Eli Lilly has announced results from the VIVID-2 open-label extension study, showing that most patients with moderately to ...

AIM To develop reproducible criteria which are valid in the assessment of acute inflammation (activity) and chronicity, and to evaluate these features ... for ulcerative colitis that showed good ...

SAN FRANCISCO -- Research presented at the annual Crohn's and Colitis Congress included studies comparing the effectiveness ...

and 72.5% maintained endoscopic remission at two years. Omvoh (mirikizumab-mkrz) is an interleukin-23p19 antagonist indicated for the treatment of moderately to severely active ulcerative colitis and ...

In particular, he said that the drug had achieved improvements in endoscopic and histologic biomarkers of ulcerative colitis, noting that “can be difficult to achieve.” The results weren’t a ...

Older adults with moderate to severe IBD can achieve remission with JAK inhibitors, according to a study presented at Crohn’s & Colitis Congress.

Pharmaceutical ads are difficult to avoid in American television programming and a growing number of them promote a class of ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

Dr L Lundell, Department of Surgery, Sahlgrenska University Hospital, S-413 45 Göteborg, Sweden. BACKGROUND Endoscopic oesophageal changes are diagnostically helpful and identify patients exposed to ...

Adults typically present with dysphagia and food impaction. No pathognomonic features have been identified for EoE and, therefore, its diagnosis must be made on both clinical and histological grounds.